NEW YORK, March 26, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing first-in-class therapies for allergic and inflammatory diseases ...

Hoth Therapeutics (HOTH) announced “promising” findings for its novel therapeutic candidate, HT-001, a topical neurokinin 1 receptor antagonist, in the treatment of Epidermal Growth Factor ...